Please use this identifier to cite or link to this item:
Title: SMARTphone Based Cardiovascular Risk Reduction in BREAST Cancer Patients (SMART-BREAST): A Randomised Controlled Trial Protocol.
Austin Authors: Murphy, Alexandra C ;Farouque, Omar ;Yeo, Belinda ;Dick, Ron;Koshy, Anoop N ;Roccisano, Laura;Reid, Christopher;Raman, Jaishankar;Kearney, Leighton G ;Yudi, Matias B 
Affiliation: Cardiology
Department of Medicine, Deakin University, Geelong, Vic, Australia
Department of Medicine, The University of Illinois, Champagne, IL, USA
Olivia Newton-John Cancer Wellness and Research Centre
Department of Medicine, University of Melbourne, Vic, Australia
School of Public Health, Curtin University, Perth, WA, Australia
Department of Cardiology, Epworth HealthCare, Melbourne, Vic, Australia
Issue Date: Sep-2021
Date: 2021-04-22
Publication information: Heart, Lung & Circulation 2021; 30(9): 1314-1319
Abstract: Breast cancer survivors are at greater risk for cardiovascular-related mortality compared to women without breast cancer. Accordingly, attention to reducing the risk of cardiovascular disease must be a priority in the long-term management of these patients. With the exponential rise in cancer survivors, there is a need for innovative cardio-oncology programs. This paper describes the study design of a randomised controlled trial assessing the effectiveness of a smartphone-based cardiovascular risk reduction program in improving physical activity and cardiovascular health in patients undergoing treatment for breast cancer. The aim of this study is to assess the efficacy and usability of a smartphone-based model of care for exercise promotion, cardiovascular risk reduction and community engagement in women undergoing treatment for breast cancer. This will be achieved by testing our personalised smartphone application "BreastMate", as an adjunct to standard care in a single-blinded, parallel, randomised controlled trial. The primary outcome of the trial is change in exercise capacity, as measured by the 6-minute walk test distance at 12 months compared to baseline. Secondary endpoints include improvements in cardiovascular risk factor status and quality of life, received dose intensity of chemotherapy and major adverse cardiovascular events. Multicentre ethical approval has been granted by the Austin Hospital (HREC/47081/Austin/2018). The analysed results will be published in a peer reviewed journal on completion of the clinical trial. SMART-BREAST has been prospectively registered with the Australia and New Zealand Clinical Trials Registry (ANZCTR12620000007932).
DOI: 10.1016/j.hlc.2021.03.271
Journal: Heart, Lung & Circulation
PubMed URL: 33896706
Type: Journal Article
Subjects: Breast cancer
Cardiovascular risk reduction
Digital health
Randomised controlled trial protocol
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Sep 29, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.